Handelsavisen
prelaunch
Companies Healthcare 2256.HK
22
2256.HK HKEX Biotechnology & Medical Research

Abbisko Cayman Ltd

HK$10,28
Open in Charts → Attach watcher ⌖
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
ROE
Net margin
Debt / equity
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Abbisko Cayman Ltd is a biotechnology and medical research company operating in the healthcare sector, primarily engaged in pharmaceuticals and medical research.

Business. Abbisko Cayman Ltd (2256.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. As specific operating segments and geographic details are not provided, the company is described at the industry level. Its primary listing is under the ticker 2256.HK.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY8 analysts
8 buy0 hold0 sell
Avg 12m price target23,05

Analyst recommendations

8 analysts · consensus Buy
Buy8
Hold0
Sell0
12-month price target
23,05
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
8 analysts · indicative
Ownership
not yet wired
Profitability
not yet wired
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 2256.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 2256.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Abbisko Cayman Ltd (2256.HK) is a biotechnology and medical research company listed on the Hong Kong Stock Exchange. The firm operates within the healthcare sector, focusing on pharmaceuticals and medical research activities. As specific operating segments and geographic details are not provided, the company is described at the industry level. Its primary listing is under the ticker 2256.HK.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    ### Capital Structure and Liquidity Abbisko Cayman Ltd has a basic and diluted share count of 716.46 million shares, indicating no immediate dilution pressure from share-based compensation or convertible instruments. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.

    ### Profitability and Returns No profitability metrics or return ratios are available for Abbisko, which limits the ability to compare its performance against industry benchmarks or cohort medians. This absence of data suggests a lack of transparency or recent financial reporting.

    ### Segments and Geographic Exposure There is no disclosed segment or geographic revenue breakdown for Abbisko, making it difficult to assess the company's exposure to different markets or product lines. This lack of detail could indicate a single-product or single-market focus, or insufficient disclosure in recent filings.

    ### Growth Trajectory No specific growth trajectory or revenue history is provided for Abbisko, which limits the ability to project future performance. Analysts have assigned a mean price target of 23.05 CNY and a median of 22.45 CNY, with a mean recommendation of 1.62 (leaning toward buy).

    ### Risk Factors The primary risk for Abbisko is the inability to assess liquidity due to missing balance-sheet data. Additionally, the lack of profitability and segment data introduces uncertainty about the company's operational health and diversification. Dilution risk is currently low, as the basic and diluted share counts are equal.

    ### Recent Events No recent filings, transcripts, or notable events are disclosed in the available data, which limits the ability to assess management commentary or strategic shifts.

    Key takeaways
    • Abbisko Cayman Ltd operates in the biotechnology and medical research sector with a high classification confidence.
    • The company has no immediate dilution pressure, as basic and diluted share counts are equal.
    • Analysts have a generally positive outlook, with a mean recommendation of 1.62 and a mean price target of 23.05 CNY.
    • Liquidity risk could not be assessed due to missing balance-sheet data.
    • No segment or geographic revenue breakdown is available, limiting visibility into diversification and exposure.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2026-03-02
    FY 2026 · Full-year highlights

    Revenue ¥612.1M, +21,4% YoY; Operating income +50,5% YoY.

    Revenue¥612.1M+21,4 % YoY
    Operating income¥119.9M+50,5 % YoY
    Net income¥55.3M+95,4 % YoY
    Free cash flow¥72.1M+62,1 % YoY
    EPS
    Operating cash flow¥79.3M+713,5 % YoY
    Financials
    Income statement
    Revenue¥612.1M
    Gross profit¥612.1M
    Operating income¥119.9M
    Net income¥55.3M
    Margins
    Gross margin100.0%
    Operating margin19.6%
    Net margin9.0%
    FCF margin11.8%
    Balance sheet
    Total assets¥2.35B
    Total liabilities¥430.2M
    Total equity¥1.92B
    Cash & equivalents¥749.0M
    Long-term debt¥303.5M
    Cash flow
    Operating cash flow¥79.3M
    CapEx-¥5.5M
    Free cash flow¥72.1M
    SBC
    P&L flow · revenue → net income
    Revenue ¥612.1MOperating costs ¥492.3MTax ¥64.5MNet income ¥55.3M
    Highlights
    • Revenue ¥612.1M, +21,4% YoY
    • Operating income +50,5% YoY
    • Net income +95,4% YoY
    • Free cash flow +62,1% YoY
    • Net margin 9.0%

    Valuation FY

    Market price
    HK$10,28
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    Net cash
    Current ratio
    Debt / equity
    ROA
    ROE
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,47
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    8
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-19 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,47
    Revenueno estimateno estimate507,9M CNY
    Operating incomeno estimateno estimate-435,9M CNY
    Full-year consensus mean (period as reported by source) · consensus in CNY. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution8 analysts
    Strong buy3
    Buy5
    Hold0
    Sell0
    Strong sell0
    12-month price targetHK$23,05 · Median HK$22,45
    Low HK$17,90High HK$32,50
    Operating income · consensus-435,9M CNY
    EPS surprise
    +119,3 %
    reported vs consensus · beat
    Revenue surprise
    +20,5 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    LowHK$17,90
    MeanHK$23,05
    MedianHK$22,45
    HighHK$32,50
    SpotHK$10,28
    +124.2 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    Source documents
    • Abbisko Cayman Ltd Market data — financials · 2026-05-26
    • Abbisko Cayman Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    2256.HKCanonical
    HKEX · HKD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-03-02 19:24 UTCEARNINGSAnnual results — FY 2026 Revenue CNY 612.1M · Net CNY 55.3M
    2025-03-03 18:24 UTCEARNINGSAnnual results — FY 2025 Revenue CNY 504.0M · Net CNY 28.3M
    2024-03-12 20:26 UTCEARNINGSAnnual results — FY 2024 Revenue CNY 19.1M · Net CNY -431.6M
    2023-03-15 16:31 UTCEARNINGSAnnual results — FY 2023 Revenue CNY 0.0M · Net CNY -495.6M
    2022-03-18 09:30 UTCEARNINGSAnnual results — FY 2022 Revenue CNY 22.7M · Net CNY -1.81B
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage